This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    27/05/23

    FDA approves Yuflyma biosimilar for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.- Celltrion USA

    Celltrion USA announced that the FDA has approved Yuflyma (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira (adalimumab) biosimilar.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    29/05/22

    MHLW (Japan)approved Rinvoq to treat Ankylosing Spondylitis.- AbbVie

    Japan’s Ministry of Health, Labor and Welfare (MHLW) approved label expansion for AbbVie’s JAK inhibitor Rinvoq (upadacitinib).

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    29/08/17

    FDA approve Cyltezo (adalimumab biosimilar) for treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and plaque psoriasis.-Boehringer.

    Boehringer Ingelheim announced that the FDA approved Cyltezo (adalimumab biosimilar), in a pre-filled syringe for the treatment of multiple chronic...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    08/02/22

    Xeljanz receives marketing authorisation from the European Commission for the treatment of active ankylosing spondylitis.

    Xeljanz receives marketing authorisation from the European Commission for the treatment of active ankylosing spondylitis.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    07/06/23

    European Commission approvals for Bimzelx for the treatment of psoriatic arthritis and axial spondyloarthritis including non-radiographic axSpA and ankylosing spondylitis

    UCB, a global biopharmaceutical company, announced that the European Commission (EC) has granted marketing authorisation for Bimzelx(bimekizumab) for the treatment of adults with active psoriatic arthritis (PsA) and adults with active axial spondyloarthritis (axSpA) including non-radiographic axSpA (nr-axSpA) and ankylosing spondylitis (AS), also known as radiographic axSpA

    Guidelines
    Guideline
    23/08/16

    BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics

    These guidelines provide evidence-based guidance for UK clinicians prescribing biologics for adult patients with axSpA. This includes the criteria for starting treatment, the choice of drug and assessing response to treatment.

    • Source: British Society for Rheumatology (BSR)
    Latest congress news
    Congress news
    15/06/17

    Low-dose CT scanning improves assessment of Ankylosing Spondylitis patients

    Sensitive method of assessing disease progression without exposure to high doses of radiation
    Blue test tubes arranged in a line, disappearing into the background
    News
    07/11/24

    CHMP recommends extending the indication for Remsima SC to include Crohns disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.- Celltrion Healthcare

    The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Remsima ((CT-P13 SC, biosimilar infliximab) from Celltrion Healthcare Hungary Kft.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    27/12/23

    Bimzelx (bimekizumab) receives approval in Japan for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis

    UCB, a global biopharmaceutical company, announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Bimzelx (bimekizumab) for the treatment of adults with psoriatic arthritis (PsA), non-radiographic axSpA (nr-axSpA) and ankylosing spondylitis (AS) who are not sufficiently responding to existing treatments

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    08/02/22

    FDA approves Xeljanz/Xeljanz XR for ankylosing spondylitis.

    Pfizer announced that the FDA has approved the supplemental New Drug Application (sNDA) for Xeljanz / Xeljanz XR (tofacitinib) for the treatment of adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.

    See more